KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study.

Pantep Angchaisuksiri, Sylvia von Mackensen, Shashikant Apte, Gary Benson, Hermann Eichler, Amy Findley, Tadashi Matsushita, Camila M Mazini Tavares, Morten Puggaard Ravn, Jameela Sathar, Laura Villarreal Martinez, Guy Young

Res Pract Thromb Haemost 9(2) 102705

PMID40166710
PMCIDPMC11957488
DOI10.1016/j.rpth.2025.102705
发表日期2025-04-01
摘要

摘要

BACKGROUND: Patient-reported outcomes (PROs) can provide useful insights into patient perception of concizumab, an anti-tissue factor pathway inhibitor monoclonal antibody intended for once-daily, subcutaneous prophylaxis for hemophilia A (HA) or hemophilia B (HB), with and without inhibitors. OBJECTIVES: To evaluate PROs from the phase 3 explorer8 study (NCT04082429). METHODS: Male patients aged ≥12 years with HA/HB without inhibitors were enrolled and randomized 1:2 to no prophylaxis/on-demand treatment (arm 1) or concizumab prophylaxis (arm 2) or allocated to concizumab prophylaxis (arms 3 and 4). PRO questionnaires included the 36-item short-form health survey version 2, Haemophilia Quality of Life Questionnaire for Adults, Hemophilia Treatment Experience Measure, and Haemophilia Patient Preference Questionnaire. RESULTS: Estimated treatment difference for change in 36-item short-form health survey version 2 "bodily pain" and "physical functioning" from baseline to week 24 between patients in arms 1 and 2 was 9.5 points (95% CI, 2.4 to 16.7) and 0.3 points (95% CI, -5.1 to 5.6), respectively. Estimated treatment difference at week 24 between patients in arms 1 and 2 was -18.0 points (95% CI, -26.4 to -9.5) for Haemophilia Quality of Life Questionnaire for Adults "total score" and -16.8 points (95% CI, -32.2 to -1.4) for "physical health." Hemophilia Treatment Experience Measure and Haemophilia Patient Preference Questionnaire results favored concizumab prophylaxis over no prophylaxis or previous treatment. CONCLUSION: PRO data from the phase 3 explorer8 study provided additional support for concizumab prophylaxis compared with no prophylaxis as a treatment option for patients with HA/HB.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。